Jim Scibetta
Chief Executive Officer

Jim Scibetta joined VectorY Therapeutics as CEO in 2024. Mr. Scibetta brings more than 20 years of executive leadership experience, building earlier stage companies developing novel therapeutics for high unmet medical needs into more mature biotechnology companies driving high value exits.

Prior to joining VectorY Therapeutics, Mr. Scibetta served as a Senior Consultant at Rock Springs Capital, a healthcare investment fund. He previously served as CEO of ImmuneID, CEO of Maverick Therapeutics leading to its acquisition by Takeda, President of Pacira BioSciences (Nasdaq: PCRX) during its IPO and growth to commercial stage, and CFO of BioEnvision (Nasdaq: BIVN), instrumental in its sale to Genzyme. He also served as CFO Merrimack Pharmaceuticals, and has served on multiple pubic company Boards, most recently Aquestive Therapeutics (Nasdaq: AQST). Prior to his biotech company-building career, Mr. Scibetta spent 13 years in healthcare investment banking.

Mr. Scibetta received his Bachelor's degree in physics from Wake Forest University and an MBA from the University of Michigan.